An update on the synthesis and antibacterial effects of carbapenems

Recent Patents on Anti-Infective Drug Discovery

Volumn 5, Issue 1, 2010, Pages 23-43

  Galal, Ahmed M ^a   Gul, Waseem ^a,b   Noreddin, Ayman M ^c   Slade, Desmond ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b ElSohly Laboratories Incorporated   (United States)

^c HAMPTON UNIVERSITY   (United States)

Author keywords

lactam antibiotics; lactamases; Antibacterial effects; Carbapenems; Resistance; Synthesis

Indexed keywords

3 (4 AMINO 1,1 DIMETHYLBUTYL) 6 (1 HYDROXYETHYL)OXAPENEM 3 CARBOXYLIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETAMIPRON; BIAPENEM; CARBACEPHEM DERIVATIVE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN DERIVATIVE; CILASTATIN; DORIPENEM; ERTAPENEM; FROPENEM; IMIPENEM; LINEZOLID; MEROPENEM; NAPHTHOL DERIVATIVE; PANIPENEM; PANIPENEM PLUS BETAMIPRON; PENEM DERIVATIVE; PENICILLIN DERIVATIVE; RAZUPENEM; SMP 601; TEBIPENEM; TEBIPENEM PIVOXIL; THIENAMYCIN; TOMOPENEM; TRIBACTAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ABDOMINAL INFECTION; AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYSTIC FIBROSIS; DIARRHEA; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EOSINOPHILIA; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; GYNECOLOGIC INFECTION; HOSPITAL INFECTION; HUMAN; HYPERTRANSAMINASEMIA; INFECTION CONTROL; LOWER RESPIRATORY TRACT INFECTION; MENINGITIS; MIXED INFECTION; NONHUMAN; PELVIC INFLAMMATORY DISEASE; PNEUMONIA; PRIORITY JOURNAL; RASH; REACTION ANALYSIS; RESPIRATORY TRACT INFECTION; SEPTICEMIA; SKIN INFECTION; SURGICAL INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CARBAPENEMS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 77953760032     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489110790112545     Document Type: Article

References (137)

1. Fleming A. The antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 1929; 10: 226-236.
2. Fleming A. The story of penicillin. Bulletin. Georgetown University: Medical Center 1955; 8: 128-132.
3. Coghill, R.D., Moyer, A.J.: US2423873 (1947).
4. Moyer, A.J.: GB618416 (1949), GB618415 (1949) and GB624411 (1949).
5. Bentley R. The development of penicillin: Genesis of a famous antibiotic. Perspect Biol Med 2005; 48: 444-452.
6. Hodgkin DC. X-ray analysis of the structure of penicillin. Adv Sci 1949; 6: 85-89.
7. Lopez R, Menendez MI, Diaz N, et al. Theoretical studies on the ring opening of β-lactams: Processes in solution and in enzymatic media. Curr Org Chem 2006; 10: 805-821.
8. Singh GS. β-Lactams in the new millennium. Part-I: Monobactams and carbapenems. Mini-Rev Med Chem 2004; 4: 69-92.
9. Bonfiglio G, Russo G, Nicoletti G. Recent developments in carbapenems. Expert Opin Invest Drugs 2002; 11: 529-544.
10. Kim OK, Fung-Tomc J. Patents on β-lactam antibacterials: January 1999 to March 2001. Expert Opin Ther Pat 2001; 11: 1267-1276
11. Essack SY. The development of β-lactam antibiotics in response to the evolution of β-lactamases. Pharm Res 2001; 18: 1391-1399.
12. Hamilton-Miller JMT. Chemical and microbiologic aspects of penems, a distinct class of β-lactams: Focus on faropenem. Pharmacotherapy 2003; 23: 1497-1507.
13. Jamieson CE, Lambert PA, Simpson, IN. in vitro Activities of novel oxapenems, alone and in combination with ceftazidime, against Gram-positive and Gram-negative organisms. Antimicrob Agents Chemother 2003; 47: 2615-2618.
14. Vessillier S, Docquier JD, Rival S, et al. Overproduction and biochemical characterization of the Chryseobacterium meningosepticum BlaB metallo-β-lactamase. Antimicrob Agents Chemother 2002; 46: 1921-1927.
15. Edwards JR, Betts MJ. Carbapenems: The pinnacle of the β-lactam antibiotics or room for improvement? J Antimicrob Chemother 2000; 45: 1-4.
16. Walsh C. Antibiotics: actions, origins, resistance. Washington: DC: ASM Press 2003.
17. Deshmukh ARAS, Bhawal BM, Krishnaswamy D, Govande VV, Shinkre BA, Jayanthi A Azetidin-2-ones, synthon for biologically important compounds. Curr Med Chem 2004; 11: 1889-1920.
18. Alcaide B, Almendros P. β-Lactams as versatile synthetic intermediates for the preparation of heterocycles of biological interest. Curr Med Chem 2004; 11: 1921-1949.
19. Alcaide B, Almendros P. Recent advances in the stereocontrolled synthesis of bi- and tricyclic-β-lactams with non-classical structure. Curr Org Chem 2002; 6: 245-264.
20. Copar A, Prevec T, Anzic B, et al. Design, synthesis and bioactivity evaluation of tribactam lactamase inhibitors. Bioorg Med Chem Lett 2002; 12: 971-975.
21. Sader HS, Gales AC. Emerging strategies in infectious diseases. New carbapenem and trinem antibacterial agents. Drugs 2001; 61: 553-564.
22. Nicolau DP. Carbapenems: A potent class of antibiotics. Expert Opin Pharmacother 2008; 9: 23-37.
23. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007; 67: 1027-1052.
24. Bryskier A. Cephems: Fifty years of continuous research. J Antibiot 2000; 53: 1028-1037.
25. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin. Nature 1940; 146: 837-842.
26. McGowan JE. Economic impact of antimicrobial resistance. Emerg Infect Dis 2001; 7: 286-292.
27. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther 2008; 6: 751-763.
28. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008; 62(Suppl. 1): i1-i9.
29. Tenover FC. Mechanisms of antimicrobial resistance in bacteria. Am J Infect Control 2006; 34(Suppl 1): S3-S10; [Discussion S64-73].
30. Wright GD. Bacterial resistance to antibiotics: Enzymatic degradation and modification. Adv Drug Deliv Rev 2005; 57: 1451-1470.
31. Schito GC. Is antimicrobial resistance also subject to globalization? Clin Microbiol Infect 2002; 8(Suppl 3): 1-8.
32. Bryskier A. Microbial efflux of antibiotics and inhibitors of efflux pumps. In: Bryskier A, Ed. Antimicrobial agents: antibacterials and antifungals. ASM Press: USA 2005; 1055-1084.
33. Netterwald J. Super drugs for super bugs. Drug Discov Dev 2008; 11: 20-22, 24.
34. th ed). ASM Press USA 2007; 1 (72).
35. Poole K. Resistance to β-lactam antibiotics. Cell Mol Life Sci 2004; 61: 2200-2223.
36. Okereke CS. Advances in the use of carbapenem antibiotics in the management of serious bacterial infections in special patient populations. I: Safety and efficacy in children and elderly patients. Curr Ther Res 2000; 61: 289-320.
37. Zeba B. Overview of β-lactamase incidence on bacterial drug resistance. Afr J Biotechnol 2005; 4: 1559-1562.
38. Terrak M. Peptidoglycan glycosyltransferase inhibition: New perspectives for an old target. Anti-Infect Agents Med Chem 2008; 7: 180-192.
39. Macheboeuf P, Lemaire D, Martins ADS, Dideberg O, Jamin M, Dessen A. Trapping of an acyl-enzyme intermediate in a penicillin-binding protein (PBP)-catalyzed reaction. J Mol Biol 2008; 376: 405-413.
40. Novak I, Chua PJ. Computational study of pharmacophores: Lactams. J Phys Chem A 2006; 110: 10521-10524.
41. Saitoh H, Sawazaki R, Oda M, Kobayashi M. Region-dependent absorption of faropenem shared with foscarnet, a phosphate transporter substrate, in the rat small intestine. Int J Antimicrob Agents 2008; 32: 267-271.
42. Kumar, N.P., Prasad, M.: WO2007039885 (2007).
43. Schurek KN, Wiebe R, Karlowsky JA, Rubinstein E, Hoban DJ, Zhanel GG. Faropenem: Review of a new oral penem. Expert Rev Anti Infect Ther 2007; 5: 185-198.
44. Georgopapadakou NH. β-Lactamase inhibitors: Evolving compounds for evolving resistance targets. Expert Opin Invest Drugs 2004; 13: 1307-1318.
45. Rodloff AC, Goldstein EJC, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006; 58: 916-929.
46. Klastersky JA. Use of imipenem as empirical treatment of febrile neutropenia. Int J Antimicrob Agents 2003; 21: 393-402.
47. Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: A review of its use in the treatment of serious bacterial infections. Drugs 2008; 68: 803-838.
48. Linden P. Safety profile of meropenem: An updated review of over 600 patients treated with meropenem. Drug Saf 2007; 30: 657-668.
49. Burkhardt O, Derendorf H, Welte T. Ertapenem: The new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother 2007; 8: 237-256.
50. Zhanel GG, Johanson C, Embil JM, et al. Ertapenem: Review of a new carbapenem. Expert Rev Anti Infect Ther 2005; 3: 23-39.
51. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003; 52: 538-542.
52. Abbanat D, Morrow B, Bush K. New agents in development for the treatment of bacterial infections. Curr Opin Pharmacol 2008; 8: 582-592.
53. Poulakou G, Giamarellou H. Doripenem: An expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens. Expert Opin Invest Drugs 2008; 17: 749-771.
54. Hagerman JK, Knechtel SA, Klepser ME. Doripenem: A new extended-spectrum carbapenem antibiotic. Formulary 2007; 42: 676, 682-684, 686, 688.
55. Walsh F. Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities. Ther Clin Risk Manage 2007; 3: 789-794.
56. Morinaga Y, Yanagihara K, Nakamura S, et al. in vivo Efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model. J Antimicrob Chemother 2008; 62: 1326-1331.
57. Koga T, Masuda N, Kakuta M, Namba E, Sugihara C, Fukuoka T. Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008; 52: 2849-2854.
58. Revill P, Serradell N, Bolos J. Tomopenem. Drugs Future 2007; 32: 37-44.
59. Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA β-lactams in development, with a focus on ceftobiprole: The first anti-MRSA lactam to demonstrate clinical efficacy. Expert Opin Invest Drugs 2007; 16: 419-429.
60. Kattan JN, Villegas MV, Quinn JP. New developments in carbapenems. Clin Microbiol Infect 2008; 14: 1102-1111.
61. Dalhoff A, Janjic N, Echols R. Redefining penems. Biochem Pharmacol 2006; 71: 1085-1095.
62. Bush K, Macielag M, Weidner-Wells M. Taking inventory: Antibacterial agents currently at or beyond Phase 1. Curr Opin Microbiol 2004; 7: 466-476.
63. Sunagawa M, Sasaki A. The structural aspects of carbapenem antibiotics. Heterocycles 2001; 54: 497-528.
64. Joseph J, Rodvold KA. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opin Pharmacother 2008; 9: 561-575.
65. Top J, Willems R, Bonten M. Emergence of CC17 Enterococcus faecium: From commensal to hospital-adapted pathogen. FEMS Immunol Med Microbiol 2008; 52: 297-308.
66. st century: Beyond the acute care hospital. Curr Opin Infect Dis 2008; 21: 372-379.
67. Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. Infect Genet Evol 2008; 8: 747-763.
68. Nicodemo AC, Paez JIG. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007; 26: 229-237.
69. Bassetti M, Nicolini L, Esposito S, Righi E, Viscoli C. Current status of newer carbapenems. Curr Med Chem 2009; 16: 564-575.
70. Edwards SJ, Clarke MJ, Wordsworth S, Emmas CE. Carbapenems versus other β-lactams in treating severe infections in intensive care: A systematic review of randomized controlled trials. Eur J Clin Microbiol Infect Dis 2008; 27: 531-543.
71. Granowitz EV, Brown RB. Antibiotic adverse reactions and drug interactions. Crit Care Clin 2008; 24: 421-442.
72. Bush K, Bradford PA. β-Lactamases: Historical perspectives. In: Bonomo RA, Tolmasky ME, Eds. Enzyme-mediated resistance to antibiotics: Mechanisms, dissemination, and prospects for inhibition. ASM Press 2007; 6: 67-80.
73. Canton R. Epidemiology and evolution of β-lactamases. In: Baquero F, Nombela C, Cassell G, Gutierrez-Fuentes J, Eds. Evolutionary biology of bacterial and fungal pathogens. ASM Press: USA 2008; 22: 249-270.
74. Queenan AM, Bush K. Carbapenemases: The versatile β-lactamases. Clin Microbiol Rev 2007; 20: 440-458.
75. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003; 52: 331-344.
76. Jacoby GA, Mills DM, Chow N. Role of β-lactamases and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 3203-3206.
77. El Amin N, Giske CG, Jalal S, et al. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: Alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates. APMIS 2005; 113: 187-196.
78. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004; 48: 3086-3092.
79. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003). Clin Microbiol Infect 2005; 11: 974-984
80. Davies SG, Hedgecock CJR, McKenna JM. A formal total asymmetric synthesis of (+)-thienamycin. Tetrahedron: Asymmetry 1995; 6: 2507-2510.
81. Shih DH, Ratcliffe RW. Preparation and antibacterial activity of 1thienamycin. J Med Chem 1981; 24: 639-643.
82. Kahan JS, Kahan FM, Goegelman R, et al. Thienamycin, a new lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J Antibiot 1979; 32: 1-12.
83. Butterworth D, Cole M, Hanscomb G, Rolinson GN. Olivanic acids, a family of β-lactam antibiotics with β-lactamase inhibitory properties produced by Streptomyces species. I. Detection, properties and fermentation studies. J Antibiot 1979; 32: 287-294.
84. Hood JD, Box SJ, Verrall MS. Olivanic acids, a family of β-lactam antibiotics with β-lactamase inhibitory properties produced by Streptomyces species. II. Isolation and characterization of the olivanic acids MM 4550, MM 13902 and MM 17880 from Streptomyces olivaceus. J Antibiot 1979; 32: 295-304.
85. Brown AG, Corbett DF, Eglington AJ, Howarth TT. Structures of olivanic acid derivatives MM 22380, MM 22381, MM 22382 and MM 22383; four new antibiotics isolated from Streptomyces olivaceus. J Antibiot 1979; 32: 961-963.
86. Box SJ, Hood JD, Spear SR. Four further antibiotics related to olivanic acid produced by Streptomyces olivaceus: Fermentation, isolation, characterization and biosynthetic studies. J Antibiot 1979; 32: 1239-1247.
87. Park SW, We JS, Kim GW, Choi SH, Park HS. Stability of new carbapenem DA-1131 to renal dipeptidase (dehydropeptidase I). Antimicrob Agents Chemother 2002; 46: 575-577.
88. Tejedor A, Torres AM, Castilla M, Lazaro JA, de Lucas C, Caramelo C. Cilastatin protection against cyclosporin A-induced nephrotoxicity: Clinical evidence. Curr Med Res Opin 2007; 23: 505-513.
89. Lo TS, Welch JM, Alonto AM, Vicaldo-Alonto EAR. A review of the carbapenems in clinical use and clinical trials. Recent Pat AntiInfect Drug Discov 2008; 3: 123-131.
90. Butler MS. Natural products to drugs: Natural product-derived compounds in clinical trials. Nat Prod Rep 2008; 25: 475-516.
91. Hayakawa M, Ito Y, Fujita I, Iseki K, Gando S. Pharmacokinetics and the most suitable regimen of panipenem/betamipron in critically ill patients receiving continuous renal replacement therapy: A pilot study. ASAIO J 2006; 52: 398-403.
92. Liu G, Li JM, Yang HP, et al. Antibacterial activity of panipenem/betamipron in vitro and its pharmacokinetics and therapeutic efficacy in patients with pulmonary infection. J Med Coll PLA 2005; 20: 119-123.
93. Goa KL, Noble S. Panipenem/betamipron. Drugs 2003; 63: 913-925.
94. Shimada J, Kawahara Y. Overview of a new carbapenem, panipenem/betamipron. Drugs Exp Clin Res 1994; 20: 241-245.
95. Talbot GH. What is in the pipeline for Gram-negative pathogens? Expert Rev Anti-Infect Ther 2008; 6: 39-49.
96. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
97. Wang Y, Bolos J, Serradell N. Tebipenem pivoxil/tebipenem: Carbapenem antibiotic. Drugs Future 2006; 31: 676-681.
98. Hotomi M, Suzumoto M, Itahashi K, et al. Efficacy of a novel oral carbapenem, tebipenem pivoxil (TBM-PI), against experimental otitis media caused by penicillin resistant Streptococcus pneumoniae in chinchilla. Vaccine 2007; 25: 2478-2484.
99. Suyama H, Ikawa K, Morikawa N, et al. Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration. Jpn J Antibiot 2008; 61: 303-313.
100. Perry CM, Ibbotson T. Biapenem. Drugs 2002; 62: 2221-2234.
101. Livermore DM, Mushtaq S, Warner M. Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms. J Antimicrob Chemother 2009; 64: 330-335.
102. Demain AL, Vaishnav P. Involvement of nitrogen-containing compounds in β-lactam biosynthesis and its control. Crit Rev Biotechnol 2006; 26: 67-82.
103. Christensen, B.G., Leanza, W.J., Wildonger, K.J.: US4194047 (1980).
104. Kumar, Y., Tewari, N., Rai, B.P.: US20040220168A1 (2004).
105. Wasserman HH, Xia M, Carr AJ, Han WT, Siegel MG. Generation of penems, carbapenems and aza analogs of cephems by the addition of heterocycles and other building blocks to azetinones. Tetrahedron 2000; 56: 5621-5629.
106. Kano, Y., Yamamoto, Y., Maruyama, T., Sawabe, T., Shitara, E., Aihara, K., Atsumi, K., Ida, T.: US20040038967A1 (2004).
107. Harris, M.A., Howie, S.L.: WO2005066175A2 (2005).
108. Hayler, J.D, Howie, S.L., Negus, A.: WO2005066174A2 (2005).
109. Kozawa Y, Mori M. Synthesis of 3-alkoxycarbonyl-1-methylcarbapenem using palladium-catalyzed amidation of vinyl halide. Tetrahedron Lett 2002; 43: 111-114.
110. Kozawa Y, Mori M. Synthesis of 3-alkoxycarbonyl-1 - methylcarbapenem by using the palladium-catalyzed C-N bondforming reaction between vinyl halide and β-lactam nitrogen. J Org Chem 2003; 68: 3064-3067.
111. Joyeau R, Kobaiter R, Sadet J, Wakselman M. Carbacephems and 4-methylene-2-azetidinones by copper-mediated amide nitrogenvinylic carbon ring closure. Tetrahedron Lett 1989; 30: 337-340.
112. Van Staden LF, Gravestock D, Ager DJ. New developments in the Peterson olefination reaction. Chem Soc Rev 2002; 31: 195-200.
113. Harris, M.A., Howie, S.L.: WO2005066173A2 (2005).
114. Choi, W.B., Kowalik, E.: WO2005123066A1 (2005).
115. Choi WB, Lee J, Lynch JE, Volante RP, Reider PJ, Reamer RA. A stereoselective synthesis of a 2-functionalized-methyl-1 -methylcarbapenem key intermediate via decarboxylation. Chem Commun 1998; 17: 1817-1818.
116. Choi, W.B., Lee, J., Lynch, J.E., Reider, P.J., Volante, R.P.: WO9910323A1 (1999).
117. Choi, W.B., Menaldino, D.S., Kim, D.I., Bouygues, M., Hager, M.W.: WO2005123069A2 (2005).
118. Bantar C. Schell C, Posse G, Limansky A, Ballerini V, Mobilia L. Comparative time-kill study of doxycycline, tigecycline, sulbactam, and imipenem against several clones of Acinetobacter baumannii. Diagn Micrbiol Infec Dis 2008; 61: 309-314.
119. Vardakas KZ, Kioumis I, Falagas ME. Association of pharmacokinetic and pharmacodynamic aspects of linezolid with Infection outcome. Curr Drug Metab 2009; 10: 2-12.
120. Cunha B.A. Vancomycin revisited: A reappraisal of clinical use. Crit Care Clin 2008; 24: 393-420.
121. Yoo, K.H., Kim, D.J., Kang, Y.K., Lee, K.S., Lee, G.S., Kim, M.S., Kang, J.H.: WO2005121144A1 (2005).
122. Sunagawa M, Matsumura H, Inoue T, Fukasawa M, Kato M. A novel carbapenem antibiotic, SM-7338 structure-activity relationships. J Antibiot 1990; 43: 519-532.
123. Hilliard NJ, Johnson CN, Armstrong SH, Quarles S, Waites KB. in vitro Activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials. Int J Antimicrob Agents 2002; 20: 136-140.
124. Kim, B.J., Kim, J.H., Kong, J.H., Cho, H., Choi, Y.R., Kim, C.S.: WO2006025634A1 (2006).
125. Tewari, N., Mane, A., Rai, B.P., Prasad, M. US2007197781A1 (2007).
126. Tewari, N., George, V., Mane, A.S., Meeran, H.N.P.N., Prasad, M.: WO2007029084A2 (2007).
127. Sunagawa, M., Isobe, Y., Takeuchi, Y., Matsumura, H., Ozaki, Y., Noguchi, T.: US4888344 (1989).
128. Sunagawa, M.: US4943569 (1990).
129. Sunagawa, M., Matsumura, H., Inoue, T., Fukasawa, M., Kato, M.: US5122604 (1992).
130. Gnanaprakasam, A., Arumugam, N., Udayampalayam, P.S., Pandian, P.S., Sivasankaran, V., Veeramani, G., Sudhan, H.S. Rao, G.V.: WO2008062279A2 (2008).
131. Williams, J.M., Brands, K.M.J., Skerlj, R.T., Houghton, P.: US20036504027B1 (2003).
132. Brands, K.M.J., Cvetovich, R., Crocker, L.S., Ward, M.D., Mahajan, A.J., Wenslow, R.M., Williams, J.M., Sidler, D.R., Orella, C., Fisher, E.S., Jobson, R.: US20067145002B2 (2006).
133. Michida, M., Nagao, Y.: US2006189592A1 (2006).
134. Kawamoto, I., Shimoji, Y., Fukuhara, H.: US2004132668A1 (2004).
135. Kawamoto, I., Shimoji, Y., Fukuhara, H.: US20030158174 (2003).
136. Rai, B.P., Tewari, N., Kumar, Y.: US20050004359A1 (2005).
137. Shin, D.G., Hong, M.C., Lee, W.K., Ha, H.J., Moon, S.C., Song, C.H., Lee, K.H., Han, C.W., Kim, J.H., Lee, B.G., Song, Y.S.: WO2008127070A1 (2008).